DK1521593T3 - Transdermale botulinumtoksinforbindelser - Google Patents

Transdermale botulinumtoksinforbindelser

Info

Publication number
DK1521593T3
DK1521593T3 DK03748935T DK03748935T DK1521593T3 DK 1521593 T3 DK1521593 T3 DK 1521593T3 DK 03748935 T DK03748935 T DK 03748935T DK 03748935 T DK03748935 T DK 03748935T DK 1521593 T3 DK1521593 T3 DK 1521593T3
Authority
DK
Denmark
Prior art keywords
botulinum toxin
neurotoxin
patient
toxin compounds
transdermal
Prior art date
Application number
DK03748935T
Other languages
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1521593T3 publication Critical patent/DK1521593T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK03748935T 2002-07-11 2003-07-08 Transdermale botulinumtoksinforbindelser DK1521593T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/194,805 US20040009180A1 (en) 2002-07-11 2002-07-11 Transdermal botulinum toxin compositions
PCT/US2003/021351 WO2004006954A2 (en) 2002-07-11 2003-07-08 Transdermal botulinum toxin compositions

Publications (1)

Publication Number Publication Date
DK1521593T3 true DK1521593T3 (da) 2009-08-03

Family

ID=30114842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03748935T DK1521593T3 (da) 2002-07-11 2003-07-08 Transdermale botulinumtoksinforbindelser

Country Status (15)

Country Link
US (5) US20040009180A1 (da)
EP (1) EP1521593B1 (da)
JP (2) JP2005538082A (da)
KR (1) KR101041698B1 (da)
CN (1) CN100546648C (da)
AT (1) ATE430579T1 (da)
AU (1) AU2003267987B2 (da)
BR (1) BR0312506A (da)
CA (1) CA2492029A1 (da)
DE (1) DE60327528D1 (da)
DK (1) DK1521593T3 (da)
ES (1) ES2323497T3 (da)
MX (1) MXPA05000134A (da)
NZ (1) NZ537231A (da)
WO (1) WO2004006954A2 (da)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US9066943B2 (en) * 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
DK1301213T3 (da) * 2000-07-21 2017-03-27 Revance Therapeutics Inc Flerkomponentsystemer til biologisk transport
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7666435B2 (en) * 2002-08-19 2010-02-23 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
WO2004084839A2 (en) * 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
HUE025656T2 (en) * 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US20080031898A1 (en) * 2004-03-26 2008-02-07 David Nathaniel E Compositions and methods to increase the effect of a neurotoxin treatment
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1796676B1 (en) * 2004-05-07 2016-03-09 Phytotox Limited Transdermal administration of phycotoxins
BRPI0510759A (pt) * 2004-05-07 2007-11-20 Phytotox Ltd método de facilitar a cura de um ferimento
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP1786459B1 (en) * 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7906124B2 (en) * 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
CA2588560A1 (en) * 2004-12-29 2006-07-06 Labo Cosprophar Ag Cosmetic composition for skin application suitable for relaxing expression wrinkles
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
ES2362301T3 (es) 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
AU2006346369B2 (en) 2005-07-18 2013-02-21 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
EP1747782A1 (en) 2005-07-19 2007-01-31 Cesare Montecucco Products for topical application comprising lysophospholipids and fatty acids
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007059528A2 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PL3144013T3 (pl) 2005-12-01 2019-04-30 Univ Of Massachusetts Lowell Nanoemulsje botulinowe
AU2013234398B2 (en) * 2005-12-01 2016-05-19 University Of Massachusetts Lowell Botulinum nanoemulsions
CN102408470A (zh) 2005-12-23 2012-04-11 洛桑大学 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
EP2015773A4 (en) * 2006-04-27 2010-05-05 Anterios Inc EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
US7445783B2 (en) * 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2008082889A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
DK2178549T3 (da) 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimikrobielt peptid og sammensætninger deraf
WO2009021232A2 (en) * 2007-08-09 2009-02-12 Massachusetts Institute Of Technology High-throughput, whole-animal screening system
CA2703370A1 (en) * 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EP2320821B2 (en) 2008-05-09 2020-12-30 Nuvaira, Inc. Systems for treating a bronchial tree
MX2010013562A (es) 2008-06-26 2011-02-15 Anterios Inc Aplicacion dermica.
US8697155B2 (en) * 2008-07-22 2014-04-15 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
DE102008034453A1 (de) * 2008-07-24 2010-02-11 Lts Lohmann Therapie-Systeme Ag Verfahren zum Herstellen eines Mehrschichtenverbundes auf einer CIP-fähigen Beschichtungsanlage und Verwendung des damit hergestellten Mehrschichtenverbundes für die transdermale Applikation oder die Applikation in Körperhöhlen
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
MX2011010335A (es) * 2009-04-01 2012-01-12 Revance Therapeutics Inc Metodos y composiciones para tratar afecciones de la piel asociadas con hiperreactividad vascular.
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CN102869373B (zh) 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
CN104856757B (zh) 2009-10-27 2017-06-23 赫莱拉公司 具有可冷却的能量发射组件的递送装置
EP4111995A1 (en) 2009-11-11 2023-01-04 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
AU2012209274A1 (en) 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
ES2720648T3 (es) 2011-01-24 2019-07-23 Anterios Inc Composiciones de nanopartículas
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
ES2604707T3 (es) * 2011-06-27 2017-03-08 Sang Duck Kim Composición farmacéutica para su uso en el tratamiento de cicatrices en la piel
US20170360867A1 (en) * 2011-11-11 2017-12-21 Nova Neura, Llc Pain Relieving System
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
GB201208384D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
US9205204B2 (en) 2012-08-06 2015-12-08 Elwha Llc Devices and methods for wearable injection guides
RU2506054C1 (ru) * 2012-10-22 2014-02-10 Елена Александровна Рогожкина Способ лечения хронической анальной трещины
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2976060B1 (en) 2013-03-22 2016-10-26 Lipotec, S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US20160279401A1 (en) 2015-03-27 2016-09-29 Allergan, Inc. Dissolvable microneedles for skin treatment
BR112016027773B1 (pt) * 2014-05-29 2023-12-26 Procell Therapeutics Inc. Proteína recombinante célula-penetrante de toxina botulínica,composição farmacêutica, composição para um agente dérmico externo e composição cosmética
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016167545A1 (ko) * 2015-04-13 2016-10-20 주식회사 엘지생활건강 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들
EP3284506B1 (en) 2015-04-13 2021-04-28 LG Household & Health Care Ltd. Soluble microneedle containing ingredient for controlling release of neurotransmitters
KR102203633B1 (ko) * 2015-04-14 2021-01-15 주식회사 엘지생활건강 칼슘채널 차단제 전달용 용해성 미세바늘
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
WO2017063743A1 (en) * 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
KR101876177B1 (ko) * 2016-02-17 2018-07-09 가톨릭관동대학교산학협력단 경피투과 보툴리눔 독소 패치
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3582752A1 (en) 2017-02-17 2019-12-25 Allergan, Inc. Microneedle array with active ingredient
CA3057302A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxin serotype e for use in cosmetic treatment
CN106890196A (zh) * 2017-04-07 2017-06-27 青岛东海药业有限公司 酪酸梭菌在制备预防或治疗帕金森病制剂中的应用
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019126502A1 (en) 2017-12-20 2019-06-27 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN118121545A (zh) * 2018-11-19 2024-06-04 奥维嘉生物科技（北京）有限公司 一种制备柔性脂质体的方法
CN113423381A (zh) 2018-12-03 2021-09-21 艾里奥治疗公司 大药剂的改进递送
MX2021009993A (es) * 2019-02-20 2021-10-26 Regresar Medical Inc Metodos y dispositivos para localizar composiciones.
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
CN114173808A (zh) * 2019-05-14 2022-03-11 艾里奥治疗公司 延迟峰值效应和/或延长反应持续时间
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
WO2023154479A1 (en) * 2022-02-10 2023-08-17 Dyve Biosciences, Inc. Formulations for transdermal administration of active agents
WO2026053109A1 (en) * 2024-09-03 2026-03-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Methods for enhancing transdermal delivery of botulinum toxins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675009A (en) * 1977-11-07 1987-06-23 Lec Tec Corporation Drug dispensing device for transdermal delivery of medicaments
AU98530S (en) 1985-06-20 1987-11-05 Novartis Ag Subdivided membrane controlled transdermal device
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
DE69434535T2 (de) * 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5587396A (en) * 1994-08-26 1996-12-24 Mary Kay Inc. Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU6034396A (en) * 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
CA2200984A1 (en) * 1995-07-25 1997-02-13 Samir S. Mitragotri Enhanced transdermal transfer using ultrasound
US6002961A (en) 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
JP2002515786A (ja) * 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． 経皮輸送の超音波増強
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
AU740999B2 (en) 1998-01-08 2001-11-22 Sontra Medical, Inc. Sonophoretic enhanced transdermal transport
EP1061951B1 (en) * 1998-02-25 2003-08-27 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19852981A1 (de) * 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
US6238683B1 (en) * 1998-12-04 2001-05-29 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US6565532B1 (en) * 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
KR100772025B1 (ko) 2000-05-26 2007-10-31 칸지 타카다 삼층구조를 갖는 비경구용 제제
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
DK1301213T3 (da) 2000-07-21 2017-03-27 Revance Therapeutics Inc Flerkomponentsystemer til biologisk transport
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
KR20140012651A (ko) * 2011-01-24 2014-02-03 안테리오스, 인코퍼레이티드 파라벤 조성물

Also Published As

Publication number Publication date
ES2323497T3 (es) 2009-07-17
MXPA05000134A (es) 2005-04-11
US9144692B2 (en) 2015-09-29
KR20050025320A (ko) 2005-03-14
EP1521593B1 (en) 2009-05-06
CN100546648C (zh) 2009-10-07
US7704524B2 (en) 2010-04-27
US20040009180A1 (en) 2004-01-15
JP2005538082A (ja) 2005-12-15
US20080220020A1 (en) 2008-09-11
BR0312506A (pt) 2005-04-12
US20050175636A1 (en) 2005-08-11
CN1668327A (zh) 2005-09-14
ATE430579T1 (de) 2009-05-15
WO2004006954A2 (en) 2004-01-22
NZ537231A (en) 2008-04-30
US20050074461A1 (en) 2005-04-07
WO2004006954A3 (en) 2004-03-25
JP2011037866A (ja) 2011-02-24
KR101041698B1 (ko) 2011-06-14
AU2003267987A1 (en) 2004-02-02
US7758871B2 (en) 2010-07-20
CA2492029A1 (en) 2004-01-22
US20060188525A1 (en) 2006-08-24
EP1521593A2 (en) 2005-04-13
AU2003267987B2 (en) 2006-08-17
DE60327528D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
BR0312506A (pt) Composições transdérmicas de toxina botulìnica
DK0759747T3 (da) Transdermal indretning til administration gennem de-epitheliseret hud
TW200616650A (en) Semi-solid delivery vehicle and pharmaceutical compositions
BRPI0516836A (pt) composições de neurotoxina cosméticas compreendendo um componente de toxina botulina e métodos
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
HU230005B1 (hu) Legalább egy D-vitamint vagy D-vitamin analóg vegyületet és legalább egy kortikoszteroidot tartalmazó külsőleges gyógyszerkészítmények
MXPA03002576A (es) Metodos para tratar lesiones musculares.
SG160357A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
AR029464A1 (es) Metodos para el tratamiento de la diabetes
BR0307496A (pt) Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária
DK1392328T3 (da) Medikament til beskyttelse i radioterapi
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
DE502005009568D1 (de) Pharmazeutische Zubereitungen als Hydrogel, die Diaminooxidase enthalten
DK1893237T3 (da) Farmaceutisk sammensætning, der omfatter en organopolysiloxan ela-stomer og et solubiliseret aktivt stof
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus